What's new? Log in Free sign up

Novartis (NVS)

Company Profile

Company profile

Ticker

NVS, NVSEF

Exchange

Website

www.novartis.com

CEO

Dr. Vasant Narasimhan M.D.

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

NVS stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Prospectus supplement for primary offering

Current report (foreign)

Free writing prospectus

Prospectus supplement for primary offering

Automatic shelf registration (foreign)

Third party tender offer statement (amended)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart NVS financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Novartis earnings reports.

Institutional ownership, Q3 2024

NVS institutional ownership history Ownership history

5.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1267	1281	-1.1%
Opened positions	99	141	-29.8%
Closed positions	113	84	+34.5%
Increased positions	405	420	-3.6%
Reduced positions	454	465	-2.4%

13F shares	Current	Prev Q	Change
Total value	13.83 tn	13.43 tn	+3.0%
Total shares	130.34 mm	137.08 mm	-4.9%
Total puts	1.83 mm	1.54 mm	+19.0%
Total calls	1.12 mm	1.48 mm	-24.8%
Total put/call ratio	1.6	1.0	+58.2%

Largest owners	Shares	Value	Change
Dodge & Cox	12.22 mm	$1.41 tn	-0.1%
Primecap Management	12.01 mm	$1.38 tn	-1.4%
Dimensional Fund Advisors	8.09 mm	$930.89 bn	+9.3%
MS Morgan Stanley	6.98 mm	$803.40 bn	-5.8%
Loomis Sayles & Co L P	5.77 mm	$663.62 mm	-3.0%
BAC Bank of America	4.96 mm	$571.00 bn	+2.5%
BEN Franklin Resources	4.38 mm	$509.05 bn	-18.0%
Wellington Management	4.00 mm	$459.99 bn	-8.8%
GS The Goldman Sachs Group, Inc.	3.49 mm	$400.99 bn	+13.1%
JHG Janus Henderson	2.54 mm	$292.36 bn	-0.3%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	1.95 mm	+1.95 mm	NEW
BLK BlackRock	0.00	-1.87 mm	EXIT
Magnetar Financial	0.00	-1.31 mm	EXIT
Mondrian Investment Partners	0.00	-1.27 mm	EXIT
BK The Bank of New York Mellon Corporation	760.63 k	-1.14 mm	-60.1%
BEN Franklin Resources	4.38 mm	-962.45 k	-18.0%
Dimensional Fund Advisors	8.09 mm	+685.34 k	+9.3%
Cullen Capital Management	2.25 mm	-618.41 k	-21.5%
Canada Pension Plan Investment Board	0.00	-606.89 k	EXIT
MS Morgan Stanley	6.98 mm	-431.81 k	-5.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts

https://www.gov.ca.gov/2024/12/18/governor-newsom-takes-proactive-action-to-strengthen-robust-state-response-to-bird-flu/#:~:text=What%20you%20need%20to%20know,ongoing%20cross%2Dagency%20response%20efforts

CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana

https://www.cdc.gov/bird-flu/situation-summary/index.html

BioAge Labs Announces Multi-Year Collaboration With Novartis To Discover Novel Targets For Therapies That Address Age-Related Diseases And Conditions; Novartis To Pay Up To $20M Comprising Upfront Payments And Research Funding; BioAge May Receive Up To $530M In Future Long-Term Research, Development, And Commercial Milestones

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

Press releases

From Benzinga Pro

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by various factors,

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

- PTC to receive $1.0B in cash at closing -- PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -- PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Ratio to receive upfront, and potential milestones and tiered royalty payments BOSTON, Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Seaport Therapeutics Names Lauren White as Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.